Haematologica (May 2012)

Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82

  • Michael Lauseker,
  • Markus Pfirrmann,
  • Verena S. Hoffmann,
  • Joerg Hasford

DOI
https://doi.org/10.3324/haematol.2011.061630
Journal volume & issue
Vol. 97, no. 5

Abstract

Read online

No abstracts available.